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Neutropenic event risk and impaired
chemotherapy delivery in six European audits
of breast cancer treatment
Abstract Goals of work: The aims
of this study were to assess chemo-
therapy treatment characteristics,
neutropenic event (NE) occurrence
and related risk factors in breast
cancer patients in Western Europe.
Materials and methods: Six retro-
spective audits of breast cancer che-
motherapy were combined into a
dataset of 2,860 individuals. NEs
were defined as neutropenia-related
hospitalisation, dose reduction ≥15%
or dose delay ≥7 days. Summation
dose intensity (SDI) was calculated to
compare different types of chemo-
therapy regimens on a single scale.
Risk factors of NE occurrence and of
low relative dose intensity (RDI)
≤85% were identified by multiple
logistic regression. Main results:
Patient populations were comparable
between audits. Until 1998, cyclo-
phosphamide, methotrexate and
fluorouracil regimens were most fre-
quently used, but thereafter, anthra-
cycline-based regimens were most
common. NEs occurred in 20% of the
patients and low RDI in 16%. NE
occurrence predicted low RDI and
was associated with higher age,
bigger body surface area, lower body
mass index, regimen type, more che-
motherapy cycles planned, normal to
high SDI, concomitant radiotherapy
and year of treatment. First cycle NE
occurrence predicted NEs from cycle
2 onwards. A risk score using age,
SDI, number of planned chemothera-
py cycles and concomitant radiother-
apy differentiated patients with
increasing NE risk (9–37%). An
alternative score version not using
concomitant radiotherapy performed
moderately less well. Conclusions:
NEs occurred frequently in this com-
bined dataset and they affected treat-
ment delivery. Identifying patients at
high NE risk enables targeted pro-
phylaxis and may avoid dose
limitations.
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Introduction
Myelosuppression is a major side effect of anticancer che-
motherapy. Consequences include potentially life-threaten-
ing febrile neutropenic episodes, intravenous antibiotic
treatment and prolonged hospitalisation [22]. Chemother-
apy dose reductions and delays are common sequelae and
may affect treatment outcomes adversely [1, 18]. In early-
stage breast cancer, adjuvant chemotherapy has become an
element of standard therapy and reduces the hazard rate of
death by about 15% [10]. However, this benefit may be
reduced or lost when relative chemotherapy dose intensity
(RDI) is reduced [2–4, 23].
Trial-based reports of chemotherapy-induced neutrope-
nia (CIN) and febrile neutropenia (FN) incidence in breast
cancer patients vary widely. During the last decade,
cyclophosphamide, methotrexate and fluorouracil (CMF)
regimens and fluorouracil, doxorubicin or epirubicin and
cyclophosphamide (FAC or FEC) regimens have been
most widely used. A systematic review of randomised
clinical trials with at least 50 patients per treatment arm
published between 1990 and 2000 found grade III–IV CIN
rates of 1–78% in CMF chemotherapy and of 3–100% in
FAC or FEC chemotherapy [8]. These differences are
partially explained by protocol-specific assessment rules
and differences in the timing of absolute neutrophil counts
(ANC) or white blood cell counts (WBC) [13]. Thus,
current evidence does not always enable a specific
neutropenia risk to be assigned to commonly used
regimens. Detailed information on the impact of neutrope-
nia on chemotherapy delivery in routine practice is also
limited.
Prophylactic measures such as colony-stimulating factor
(CSF) and anti-infectives administration can be used to
avoid neutropenic event (NE) occurrence and maintain
RDI. Current US and European guidelines, as well as
economic constraints, recommend a limited use of such
prophylaxis, and this is reflected in practice [9, 13, 21, 22].
Furthermore, new National Comprehensive Cancer Net-
work myeloid growth factor guidelines recommend that the
overall risk of neutropenia should be calculated, taking into
account both patient and treatment risk factors, before
deciding whether to provide growth factor support [21].
Thus, the development of clinically applicable risk models
allowing prophylaxis to be targeted at high-risk patients is
important. Various studies published during the last decade
have addressed this, and research is currently ongoing [19].
Results are awaited from ongoing American and European
prospective observational studies.
We have combined data from six retrospective European
audits of breast cancer chemotherapy, enabling us to assess
the incidence and extent of chemotherapy dose limitations,
the incidence of NEs and the associations of both with
potential risk factors with greater statistical power than the
individual audits. From these analyses, we propose
preliminary NE risk scores.
Materials and methods
Datasets combined
Data on NE occurrence and impaired chemotherapy
delivery were obtained from six audits in which patient
identification information had been removed. Details of the
Chemodose 99 audit conducted in 37 centres in Belgium
and Luxembourg, the Optimización del Standard de
Quimioterapia Administrada en diferentes Regímenes
audit conducted in 34 Spanish centres, the Audit of
Primary Breast Cancer Patients conducted in 15 UK district
general and teaching hospitals and an audit conducted in
six German centres were reported earlier [6, 15–17].
Unpublished data came from two academic centres in
Vienna, Austria (principal investigator L. Auerbach) and in
Ghent, Belgium (principal investigator S. Van Belle).
In the UK audit, data were collected prospectively in
60% of the patients. All other data were collected
retrospectively. Patient selection rules were designed to
recruit a patient mix as seen in routine practice, but rules
regarding the inclusion of stage IV patients differed
between audits, and the Belgian (Ghent) study only
included patients receiving adjuvant CMF regimens.
Variables available from all six audits comprised
demographic details, diagnosis and disease stage, prog-
nostic factors and hormone receptor status (except UK
audit), planned and administered chemotherapy, toxicities,
NEs and related hospitalisations, concomitant radiotherapy
and CSF use. Some ANC andWBC values were missing in
all audits. Comorbidity and performance status data were
not available, although the latter were unlikely to be
important in a mostly adjuvant setting. Limited information
on long-term outcome was available from the Austrian,
German and Spanish audits but not from the rest.
Coding and grouping criteria were unified. Variable
definitions were compared and in discrepant or unclear
cases, recalculations were performed from the cycle-
specific details available. With respect to chemotherapy
dose limitations, cut-off points used were ≥15% for
reductions and ≥7 days for delays. RDI was calculated as
administered dose per unit time divided by planned dose
per unit time. In the case of combination regimens, the
RDIs for each drug were averaged. Low RDI was defined
as RDI ≤85% [2]. NEs were defined as neutropenia-related
dose delay, dose reduction or hospitalisation. The decision
whether events were neutropenia-related was made by the
original investigators. Due to a lack of uniform assessment
rules, ANC or WBC data were frequently missing and thus
could not be used to verify NEs for the combined dataset.
Summation dose intensity (SDI), measuring the planned
dose intensity of combination regimens on a single
summary scale, was calculated as proposed by Hryniuk
et al. [14]. From first-line single-agent trials in metastatic
breast cancer, these authors determined the unit dose
intensity (UDI) required for each drug to produce a 30%
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complete plus partial response rate. For each regimen, the
dose intensities of the individual agents used were
expressed as fractions of their UDIs and were summed.
In this study, the resulting SDI values were standardised to
a recognised ‘standard’ of chemotherapy, namely, intrave-
nous CMF with drug administrations on days 1 and 8 of a
28-day cycle in the following doses (mg m−2): cyclophos-
phamide, 600; methotrexate, 40; 5-fluorouracil 600 [CMF
600–40–600 in days 1 and 8 for 4 weeks (d1,8 4w)]. An
RDI adjusted to CMF 600–40–600 in days 1 and 8 for
4 weeks was then calculated by multiplication with the
standardised SDI values (adjusted RDI).
Statistical methods
Descriptive analysis used standard statistical methods.
Univariate relationships between categorical variables
were assessed by chi-squared tests. Where one variable
was continuous, t tests and ANOVA or Mann–Whitney U
tests and Kruskal–Wallis tests were used, depending on the
distributions observed. Where both variables were contin-
uous, Spearman’s correlation coefficients were employed
because of non-normality.
Multiple logistic regression allowing for clustering by
audit was used to calculate adjusted odds ratios (OR) with
robust standard errors for the following outcomes: any NE
occurrence, NE occurrence from cycle 2 onwards and low
RDI [24].
Chemotherapy delays and dose reductions directly
impacted on RDI and they were also part of the NE
definition used. As a consequence of this circularity, the
coefficient of the NE covariate may have been over-
estimated in the regression models on low RDI occurrence.
Therefore, this was checked by using an alternative NE
definition based on the limited ANC and WBC data
available.
The independent influences on NE occurrence identified
in regression analysis were used as candidate items for the
development of tentative NE risk scores. Selection of score
items followed the principle of achieving a maximum of
predictive and discriminatory power with a minimum of
complexity. Cut-off points for continuous variables were
chosen empirically to optimise score performance.
Two-tailed p=0.05 was used to determine statistical
significance. Confidence intervals (CIs) shown are at the
95% level.
Results
Patient and treatment characteristics
The Austrian, Belgian and Luxembourg, Belgian (Ghent),
German, Spanish and UK audits contributed 375, 660, 82,
154, 1,167 and 422 patients (total 2,860), respectively. Of
these, 79% received their chemotherapy treatments during
1995–2001.
Table 1 Patient, disease and treatment characteristics
Variable N total All audits Inter-audit range
Age at diagnosis (years; mean±SD) 2,745* 51.5±11.3 48.0±10.9 – 53.1±11.8
Age at diagnosis 60 years or higher (%) 2,745* 24.4 13.6 – 30.7
Menopausal status (% postmenopausal)*** 2,365** 51.5 44.0 – 56.8
Hormone receptor status (% positive) 2,179** 63.7 56.3 – 70.9
Disease stage***
stage I (%) 2,743* 18.1 14.6 – 21.6
stage II (%) 62.5 54.9 – 69.0
stage III (%) 15.5 10.4 – 28.9
stage IV (%) 4.0 0.0 – 8.9
Chemotherapy regimen****
CMF-based (%) 2,834* 55.7 47.0 – 72.3
Anthracycline-based (%) 40.8 27.3 – 47.2
Taxane-based (%) 1.3 0.0 – 3.0
Others (%) 2.2 0.3 – 7.3
Concomitant radiotherapy (%) 2,606* 30.9 23.7 – 61.6
Colony-stimulating factor use (%) 2,832* 12.9 1.4 – 18.3
*N total <2,860 due to missing values spread over various datasets
**N total <2,860 due to inavailability of UK data and additional missing values spread over various datasets
***Inter-audit ranges of menopausal status and disease stage do not take into account the Belgian (Ghent) dataset (see text).
****Inter-audit ranges of chemotherapy regimens used do not take into account the Belgian (Ghent) audit reporting data on patients
receiving CMF chemotherapy only
C Cyclophosphamide, F 5-fluorouracil, M methotrexate
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Patient and disease characteristics were acceptably
similar across audits (Table 1). However, the diagnostic
spread in the Belgian (Ghent) audit was unusual with an
increased proportion of stage I patients (32 vs 18% across
all audits) and a reduced proportion at stage III (4 vs 16%
across all audits). Post-menopausal patients were under-
represented in this dataset, although other patient char-
acteristics were comparable to other audits.
In total, 240 different chemotherapy regimens were
planned. A comparison of these regimens was facilitated
by the use of SDI [14], using CMF 600–40–600 d1,8 4w
as a standard. Table 2 details the distribution of the
most common regimen subtypes and their standardised
SDI values, and Fig. 1 shows a histogram of standardised
SDI. Mean SDI was highest in CMF chemotherapy,
followed by anthracycline-based, taxane-based and other
chemotherapy. Older patients generally received lower
SDI regimens (correlation coefficient −0.10, p<0.001),
more so in CMF (−0.13, p<0.001) than in anthracycline-
based chemotherapy (−0.07, p<0.001).
Concomitant radiotherapy was administered to 40% of
the patients receiving CMF-based chemotherapy and to 22,
14 and 16% of those receiving anthracycline-based,
taxane-based and other regimens, respectively. CSFs
were used in 12% of the patients receiving CMF-based
chemotherapy and in 14, 30 and 17% of those receiving
anthracycline-based, taxane-based and other regimens,
respectively.
Since 1996, the use of CMF regimens and concomitant
radiotherapy has decreased, while the use of anthracycline-
based regimens has increased, becoming the most frequent
regimen type after 1998. The use of CSFs increased in the
early 1990s and remained relatively constant after 1995.
Chemotherapy dose limitations
Dose delays in at least one cycle occurred in 34% of the
patients (inter-audit range 16–48%), of which 8% had
delays that appeared to be directly related to concomitant
radiotherapy administration; whether they were pre-
planned chemotherapy interruptions could not be assessed.
Dose reductions in at least one cycle occurred in 33% of the
patients (inter-audit range 14–49%). Forty-seven percent
had either dose delays or dose reductions (inter-audit range
26–58%). Mean RDI±SD was 94±11% (inter-audit range
90±16%−96±8%). Figure 2 shows details by regimen type.
RDI ≤85% occurred in 16% of the patients (inter-audit
range 7–25%). It occurred more frequently in CMF-based
than in anthracycline-based chemotherapy (16 vs 14%;
p=0.052). However, anthracycline-based regimens tended
to have a lower SDI than CMF-based regimens, and when
RDI was adjusted to CMF 600–40–600 d1,8 4w chemo-
therapy, 45% of the patients fell short of the 85% threshold
(inter-audit range 10–56%).
Table 2 Frequency of use and standardised* summation dose intensity (SDI) of subtypes of planned chemotherapy regimens
Regimen subtype N total** Frequency within
regimen type (%)
SDI (mean±SD) SDI inter-audit range (mean±SD)
All regimens 2,832 – 0.92±0.19 0.84±0.19 – 1.00±0.00
CMF-based regimens
All CMF-based 1,578 – 0.94±0.17 0.85±0.21 – 1.02±0.10
CMF, 28 day cycle 1,012 64.1 0.99±0.11 0.86±0.20 – 1.07±0.00
CMF, 21-day cycle 375 23.8 0.76±0.21 0.69±0.00 – 1.03±0.32
CMF, oral 187 11.9 1.04±0.04 1.03±0.08 – 1.04±0.06
CMF-based sequential 4 0.3 0.66±0.23 0.55±0.07 – 1.00±–
Anthracycline-based regimens
All anthracycline-based 1,155 – 0.89±0.20 0.76±0.28 – 0.95±0.22
FAC 194 16.8 1.05±0.12 0.97±0.00 – 1.05±0.07
FEC 420 36.4 0.82±0.92 0.61±0.00 – 0.84±0.13
AC 138 12.0 1.00±0.07 0.90±0.20 – 1.02±0.06
EC 154 13.3 0.77±0.29 0.69±0.22 – 1.00±0.46
A→CMF 63 5.5 0.83±0.09 0.79±0.04 – 1.00±0.05
Anthracycline- and taxane-containing 38 3.3 1.21±0.43 0.98±0.03 – 1.25±0.45
Other anthracycline 148 12.8 0.88±0.22 0.79±0.10 – 1.00±0.56
Taxane-based 37 – 0.86±0.34 0.82±0.27 – 1.89±–
Others 62 – 0.70±0.08 0.63±0.21 – 0.70±0.07
*Standardised to intravenous CMF 600–40–600 d1,8 4w
**N total <2,860 due to missing values spread over various datasets
A Doxorubicin, C cyclophosphamide, E epirubicin, F 5-fluorouracil, M methotrexate
A→CMF refers to sequential regimens where several courses of A, then several courses of CMF, are administered
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RDI was slightly lower in older patients (correlation
coefficient −0.07, p=0.001). However, the proportion of
patients over age 60 who received RDI ≤85% was not
significantly higher than for patients below 60 years (17 vs
15%, p=0.270). In contrast, the proportion of patients
above 60 years who received adjusted RDI ≤85% was
higher than for younger patients (51 vs 43% below
60 years; p<0.001).
Neutropenic event occurrence
NEs (neutropenia-related dose delays, dose reductions or
hospitalisations) were observed in 20% of the patients
(inter-audit range 15–25%), and repeated NEs in 8% (inter-
audit range 6–11%). Neutropenia-related dose delays were
seen in 13% (inter-audit range 6–22%), dose reductions in
6% (inter-audit range 1–11%) and hospitalisations in 5%
(inter-audit range 4–13%). Figure 3 shows details by
regimen type.
Neutropenic event occurrence (regression results)
In logistic regression, NE occurrence was associated with
higher age, higher BSA, lower BMI, regimen type, more
planned chemotherapy cycles, normal to high SDI (second
to fourth quartiles), concomitant radiotherapy administra-
tion and year of treatment. Concomitant radiotherapy
administration interacted with BSA, number of planned
chemotherapy cycles, regimen type and SDI. The change in
NE risk over time was regimen-dependent. Table 3 details
the model.
Fig. 3 Neutropenic events by regimen type
Fig. 1 Histogram of standar-
dised summation dose intensity
(SDI)
Fig. 2 Chemotherapy dose limitations by regimen type
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NE risk over time decreased for four-weekly CMF and
anthracycline-based regimens, increased for taxane-based
and other regimens and increased then decreased for three-
weekly CMF. Three-weekly CMF had a distinctly higher
NE risk compared to four-weekly CMF. Taxane-based
regimens also posed a greater NE risk than four-weekly
CMF, although the sample was rather small (N=37). For
anthracycline-based regimens, the NE risk was only
slightly greater than for four-weekly CMF when time
trends were taken into account.
A positive association of concomitant radiotherapy and
NE occurrence was confirmed for patients receiving four-
weekly CMF regimens with normal to high SDI (41% of
our sample), with an OR of 2.5 (CI 1.4–4.5; calculated
from the linear predictors underlying the ORs shown in
Table 3, using mean values for body surface area and
number of planned chemotherapy cycles). The use of
Table 3 Influences on any neutropenic event occurrence (logistic regression allowing for clustering by audit)
N=2,358 Pseudo R squared of the model = 0.070
Independent variable Odds ratio (95% CI) p*
Age** 1.02 (1.01–1.03) <0.001
Body surface area** If concomitant radiotherapy no 3.85 (1.84–8.07) <0.001
If concomitant radiotherapy yes 0.95 (0.47–1.95) 0.895
If concomitant radiotherapy unknown 13.19 (2.38–73.11) 0.003
Body mass index** 0.97 (0.94–0.99) 0.013
Chemotherapy regimen*** Three-weekly CMF 2.75 (2.05–3.67) <0.001
Anthracycline-based 1.50 (0.98–2.30) 0.061
Taxane-based 1.68 (1.44–1.97) <0.001
Others 0.87 (0.34–2.21) 0.764
Normal to high SDI**** 1.70 (1.43–2.02) <0.001
Planned chemotherapy cycles** If concomitant radiotherapy no 1.43 (1.18–1.74) <0.001
If concomitant radiotherapy yes 1.18 (1.13–1.22) <0.001
If concomitant radiotherapy unknown 0.92 (0.81–1.03) 0.153
Year of treatment** Linear, if four-weekly CMF 0.94 (0.88–1.00) 0.068
Linear, if three-weekly CMF 1.02 (0.93–1.13) 0.626
Linear, if anthracycline use 0.85 (0.75–0.95) 0.007
Linear, if taxane-based regimen 1.91 (1.69–2.14) <0.001
Linear, if other regimen 1.50 (1.44–1.56) <0.001
Squared 0.99 (0.98–1.00) 0.075
Concomitant radiotherapy***** Yes, if four-weekly CMF 0.65 (0.42–1.00) 0.049
Yes, if three-weekly CMF 0.37 (0.20–0.70) 0.002
Yes, if anthracycline-based 0.26 (0.21–0.33) <0.001
Yes, if taxane-based – –
Yes, if other regimen – –
Unknown, if four-weekly CMF 1.01 (0.01–97.00) 0.995
Unknown, if three-weekly CMF 1.25 (0.01–123.96) 0.925
Unknown, if anthracycline-based 2.27 (0.04–116.86) 0.683
Unknown, if taxane-based – –
Unknown, if other regimen****** 76.27 (2.20–2,644.20) 0.017
Yes, if low SDI 41.27 (5.37–316.85) <0.001
Yes, if normal to high SDI 128.50 (15.99–1,032.9) <0.001
Unknown, if low SDI – –
Unknown, if normal to high SDI 1.19 (0.14–10.14) 0.876
*Combined Wald tests, for all sets of categorical or ordinal variables and for all sets of interaction terms, p<0.05. Interaction effects are
presented as simple effects, not as main effects plus interaction terms, for ease of interpretation
**Per one unit increase
***Compared to four weekly CMF
****Second to fourth quartiles compared to first quartile
*****Compared to no concomitant radiotherapy administration
******Parameter estimate based on four observations, assumed to be an artefact
C Cyclophosphamide, F 5-fluorouracil, M methotrexate, SDI summation dose intensity
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radiotherapy weakened both the association of NE risk
with higher BSA and with the number of planned
chemotherapy cycles.
First cycle NE occurrence was a strong predictor of NE
occurrence from cycle 2 onwards, with an OR of 7.7 (CI
4.3–13.9). Otherwise, influence variables and observed
interactions were as described for NE occurrence in any
cycle, and coefficients were remarkably similar.
When the observations used for model estimation were
restricted to patients receiving CMF- or anthracycline-
based chemotherapy, the associations and coefficients seen
remained largely stable.
Neutropenic event risk scores
A drug-independent risk score based on age (≥50 vs
<50 years), SDI (second to fourth quartiles vs lowest
quartile, corresponding to a standardised SDI cut-off of
0.80), number of planned chemotherapy cycles (≥6 vs <6)
and concomitant radiotherapy administration performed
best. The score value was derived by counting the number
of risk factors present and by adding 1 if there were more
than six chemotherapy cycles planned. Patient groups with
an increasing risk of NE occurrence in any cycle of 9–37%
were differentiated (Fig. 4, upper half). The area under the
receiver operating characteristic (ROC) curve was 0.60 (CI
0.58–0.63). When the suggested cut-off point of more than
two risk factors being present was used, sensitivity was
69% and specificity 47%. Omitting concomitant radiother-
apy administration as a score item reduced the area under
the ROC curve to 0.57 (Fig. 4, lower half). Sensitivity was
reduced to 51% and specificity increased to 61%.
When first cycle NE occurrence was included as an
additional score item, patient groups with an increasing risk
of NE occurrence from cycle 2 onwards (8–43%) were
differentiated with sensitivity 71% and specificity 46%.
Omitting concomitant radiotherapy administration from
this score led to a similar degradation of performance as
described above for any NE occurrence.
Low RDI occurrence (regression results)
Logistic regression showed low RDI occurrence to be
significantly associated with NE occurrence, higher stage
of disease, regimen type, concomitant radiotherapy
administration and year of treatment. When the alternative
NE definition, based on the available blood cell count data,
was used, the OR of low RDI for NE occurrence was
reduced from 5.1 (CI 4.2–6.2) to 2.5 (CI 2.1–3.1). All other
coefficients remained stable.
Discussion
This is the first multi-country study to address the
incidence, risk factors and consequences of neutropenic
events induced by adjuvant breast cancer chemotherapy.
Six retrospective European audits of breast cancer chemo-
therapy, with comparable patients (similar to those seen in
routine practice), were combined to generate the first
transnational European database.
The most commonly followed regimens were CMF- and
anthracycline-based, with administration of taxane-based
and other regimens being too rare to allow reliable results.
CSF use was low and followed no coordinated approach,
which, from an analytical perspective, may have been
advantageous because physiological relationships were not
hidden by effective prophylaxis.
NEs and low RDI were confirmed to be frequent events
and several independent predictors of NE occurrence were
identified. SDI was demonstrated to be such a predictor, for
the first time according to our knowledge. Using a cut-off
point between the first and the second quartile of the SDI
distribution was optimal for prediction purposes, but
treating SDI as a continuous variable also produced
significant results. Using SDI was crucial in separating
Fig. 4 Neutropenic events in any cycle by risk score
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the effects of regimen type from those of planned dose
intensity.
A higher NE risk in three-weekly compared to four-
weekly CMF was observed in the Spanish and UK audits;
i.e. all audits with a substantial proportion of three-weekly
CMF patients. This association has been previously
reported [12, 17], and different centre characteristics have
been proposed as a partial explanation [17]. The NE risk of
anthracycline-based regimens was only moderately in-
creased compared to four-weekly CMF, but an element of
incomplete adjustment may be present in this result as we
corrected for SDI but not for anthracycline dosage directly.
Changes in NE risk over time and dependent upon regimen
type may have been due to increasing experience and
changes in medical practice.
NE risk was shown to increase linearly with age, an
observation supported by earlier studies [1, 26]. Correcting
for SDI was important for detecting this relationship, which
was partially hidden by a tendency to use lower planned
dose intensity in older patients. While the association of
age and NE risk appears marginal when expressed per year
of age (OR 1.02; see Table 3), this corresponds to an OR of
around 1.5 for an age difference of 25 years. An increased
NE risk in patients with higher BSA and a protective effect
of higher BMI were also demonstrated. This seems
biologically plausible, particularly if it is acknowledged
that BSA-based chemotherapy dosing may not be an
optimal solution. The BSA effect was diluted in patients
receiving concomitant radiotherapy, which might be
because radiotherapy adds a BSA-independent risk com-
ponent. Concomitant radiotherapy administration itself
appeared to be associated with a higher NE risk in
univariate analysis; in multivariate analysis, this finding
was only unequivocal for four-weekly CMF regimens with
normal to high SDI.
Of the variables analysed, a combination of age, SDI,
number of planned chemotherapy cycles, concomitant
radiotherapy administration and first cycle NE (in the case
of NEs occurring from cycle 2 onwards) provided the best
indicator of risk. Tentative addition of score items
representing BSA, BMI or chemotherapy regimen type
did not improve performance. The observed wide variety of
regimen specifications, which is in part reflected in the SDI
variable, and differences in practice patterns may have
obscured the differences between the main types of
chemotherapy regimens involved. In support of our
conclusions, age, radiotherapy administration and first
cycle NE have previously been used in clinical prediction
models [7, 25, 26]. However, the cut-off found for age, at
50 years, may have been influenced by practice patterns
and may not be universally applicable. Compared to scores
derived from datasets with more baseline and first cycle
haematology parameters available, our tentative scores
performed only slightly less well [26]. Omitting concom-
itant radiotherapy, which is becoming rare, affected the
performance moderately. The other parameters used,
including SDI, can be expected to become important
components of future risk models combining patient-
related and treatment-related factors.
An association of NE and low RDI was confirmed even
when NEs were assessed from the limited ANC and WBC
values available. Low adjusted RDI was found to occur
more frequently in anthracycline-based compared to CMF-
based chemotherapy due to lower SDI values in the former.
In contrast, Lyman et al. reported lower SDI values in
CMF- than in anthracycline-based chemotherapy in the US
[20].
Our findings underline the importance of early prophy-
laxis. NEs are frequent and they often impact on chemo-
therapy delivery, with the likely effect of diminished
efficacy. The importance of maintaining full chemotherapy
dose intensity, in younger and older patients, has been
described by several authors [2–4, 23]. A current tendency
toward dose-dense regimens may further exacerbate this
problem [5, 11, 27].
To further our current findings on the risk of NE, a
prospective study measuring all potential risk factors
including first cycle ANC has commenced in Europe.
This will allow our findings to be validated against an
external dataset, and should allow our risk score to be
developed and refined to a model with increased
discriminatory power. Such a risk model is becoming
fundamentally important as economic constraints and
current guidelines require expensive prophylactic treat-
ments to be targeted to those at greatest risk [21].
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